Strumento inattivo

Altre lingue Vifor Pharma AG Other OTC

Azioni

GNHAF

CH0364749348

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	02/05/23
Court Cancels Public Shares of Vifor Pharma after Merger with CSL	14/12/22
Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	03/11/22
Australia's CSL raises annual profit forecast on Swiss acquisition	17/10/22
Vifor Pharma Gets Approval To Delist From Swiss Bourse	12/10/22
Isabelle Welton nuova presidente del cda della NZZ	04/10/22
Fitch Pulls Vifor Pharma's Rating After CSL Takeover	25/08/22
Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	23/08/22
Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	22/08/22
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	18/08/22
Australia biotech giant CSL reports profit dip, flags cost spiral	17/08/22
Australia's CSL Closes Vifor Pharma Purchase	11/08/22
CSL Completes Vifor Pharma Acquisition	10/08/22
CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.	09/08/22
Vifor Pharma Announces Resignation of Abbas Hussain as CEO	02/08/22
CSL Receives All Regulatory Approvals for Vifor Pharma Acquisition	02/08/22
Australia's CSL Further Delays Settlement Of Vifor Pharma Takeover	13/07/22
Landos Biopharma Appoints Gregory Oakes Chief Executive Officer	21/06/22
European Commission to Probe Vifor Pharma Over Alleged Anti-Competitive Behavior	20/06/22
EU regulators investigate Vifor Pharma over anti-competitive behaviour	20/06/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Vifor Pharma AG Other OTC

Azioni

GNHAF

CH0364749348

Altre lingue

Filtri